COYA Insider Trading
Insider Ownership Percentage: 12.00%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00
Coya Therapeutics Share Price & Price History
Current Price: $6.02
Price Change: ▲ Price Increase of +0.02 (0.33%)
As of 12/5/2025 05:00 PM ET
Coya Therapeutics Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 11/14/2024 | David S Snyder | CFO | Buy | 1,800 | $7.19 | $12,942.00 | 8,800 |  |
| 11/11/2024 | Arun Swaminathan | CEO | Buy | 5,000 | $7.34 | $36,700.00 | 5,000 | |
| 11/11/2024 | Fred Grossman | Insider | Buy | 2,710 | $7.37 | $19,972.70 | 2,710 | |
Coya Therapeutics Institutional Trading History
| Reporting Date | Hedge Fund | Shares Held | Market Value | % of Portfolio | Quarterly Change in Shares | Ownership in Company | Details |
|---|
| 11/26/2025 | Lantern Wealth Advisors LLC | 11,575 | $66K | 0.0% | N/A | 0.055% |  |
| 11/17/2025 | Susquehanna International Group LLP | 33,355 | $0.19M | 0.0% | -33.5% | 0.159% | |
| 11/17/2025 | Prosperity Wealth Management Inc. | 23,800 | $0.14M | 0.0% | +16.4% | 0.114% | |
| 11/17/2025 | Citadel Advisors LLC | 65,240 | $0.37M | 0.0% | +51.3% | 0.312% | |
| 11/14/2025 | Dauntless Investment Group LLC | 153,021 | $0.87M | 0.5% | +199.5% | 0.914% | |
| 11/13/2025 | CM Management LLC | 300,000 | $1.71M | 1.4% | +50.0% | 1.792% | |
| 11/7/2025 | Vanguard Group Inc. | 836,393 | $4.77M | 0.0% | -0.5% | 4.996% | |
| 11/7/2025 | JPMorgan Chase & Co. | 5,000 | $28K | 0.0% | N/A | 0.030% | |
| 8/13/2025 | Northwestern Mutual Wealth Management Co. | 20,626 | $0.12M | 0.0% | N/A | 0.123% | |
| 7/29/2025 | AIGH Capital Management LLC | 1,105,622 | $6.36M | 2.9% | -6.6% | 6.609% | |
| 5/19/2025 | Jane Street Group LLC | 26,137 | $0.17M | 0.0% | +101.7% | 0.156% | |
| 5/9/2025 | Charles Schwab Investment Management Inc. | 10,000 | $65K | 0.0% | N/A | 0.060% | |
| 5/9/2025 | CM Management LLC | 200,000 | $1.29M | 1.3% | +25.0% | 1.196% | |
| 5/7/2025 | Dauntless Investment Group LLC | 167,378 | $1.08M | 1.3% | N/A | 1.001% | |
| 5/6/2025 | AIGH Capital Management LLC | 1,183,780 | $7.66M | 3.2% | -1.4% | 7.078% | |
| 2/17/2025 | DME Capital Management LP | 1,646,440 | $9.43M | 0.5% | +29.2% | 9.853% | |
| 2/14/2025 | Jane Street Group LLC | 12,961 | $74K | 0.0% | N/A | 0.078% | |
| 2/14/2025 | Northern Trust Corp | 28,549 | $0.16M | 0.0% | +12.2% | 0.171% | |
| 2/14/2025 | Tower Research Capital LLC TRC | 5,252 | $30K | 0.0% | +1,005.7% | 0.031% | |
| 2/13/2025 | XTX Topco Ltd | 10,299 | $59K | 0.0% | N/A | 0.062% | |
| 2/12/2025 | Geode Capital Management LLC | 150,576 | $0.86M | 0.0% | +5.8% | 0.901% | |
| 2/12/2025 | AIGH Capital Management LLC | 1,201,152 | $6.88M | 2.2% | +85.0% | 7.188% | |
| 2/7/2025 | CM Management LLC | 160,000 | $0.92M | 0.8% | +11.1% | 0.958% | |
| 1/28/2025 | Newbridge Financial Services Group Inc. | 70,000 | $0.40M | 0.1% | N/A | 0.419% | |
| 11/16/2024 | Geode Capital Management LLC | 142,309 | $0.92M | 0.0% | +3.3% | 0.852% | |
| 10/24/2024 | GHP Investment Advisors Inc. | 26,171 | $0.17M | 0.0% | N/A | 0.179% | |
| 8/9/2024 | Renaissance Technologies LLC | 16,700 | $0.10M | 0.0% | N/A | 0.114% | |
| 8/1/2024 | Gilbert & Cook Inc. | 10,000 | $61K | 0.0% | N/A | 0.068% | |
| 5/10/2024 | Vanguard Group Inc. | 847,490 | $8.41M | 0.0% | +772.3% | 5.804% | |
| 2/15/2024 | Greenlight Capital Inc. | 1,274,026 | $9.44M | 0.5% | +172.2% | 12.702% | |
| 2/12/2024 | AIGH Capital Management LLC | 1,031,977 | $7.38M | 2.9% | +92.6% | 10.289% | |
| 2/9/2024 | Worth Venture Partners LLC | 92,667 | $0.69M | 0.4% | -30.8% | 0.924% | |
| 11/15/2023 | Worth Venture Partners LLC | 134,006 | $0.52M | 0.3% | -8.5% | 1.336% | |
| 11/13/2023 | AIGH Capital Management LLC | 535,794 | $2.06M | 1.0% | -8.7% | 5.342% | |
| 11/7/2023 | CM Management LLC | 100,000 | $0.38M | 0.4% | +66.7% | 1.005% | |
| 8/14/2023 | Mirador Capital Partners LP | 15,361 | $63K | 0.0% | N/A | 0.154% | |
| 8/4/2023 | CM Management LLC | 60,000 | $0.24M | 0.2% | N/A | 0.603% | |
| 2/16/2023 | AIGH Capital Management LLC | 560,000 | $2.65M | 0.9% | N/A | 5.785% | |
Data available starting January 2016
Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a low-dose interleukin 2 Treg-enhancing biologic, which is in Phase 2 clinical trial for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an antigen directed Treg-derived exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. The company was incorporated in 2020 and is headquartered in Houston, Texas.
Read More on Coya Therapeutics
Volume
150,411 shs
Average Volume
159,678 shs
Market Capitalization
$125.94 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.2
Who are the company insiders with the largest holdings of Coya Therapeutics?
Who are the major institutional investors of Coya Therapeutics?
Which major investors are selling Coya Therapeutics stock?
During the last quarter, COYA stock was sold by these institutional investors:
- Susquehanna International Group LLP
- Vanguard Group Inc.
Which major investors are buying Coya Therapeutics stock?
Within the last quarter, COYA stock was purchased by institutional investors including:
- Dauntless Investment Group LLC
- CM Management LLC
- Citadel Advisors LLC
- Lantern Wealth Advisors LLC
- JPMorgan Chase & Co.
- Prosperity Wealth Management Inc.
Within the last year, these company insiders have bought Coya Therapeutics stock:
- David S Snyder (CFO)
- Arun Swaminathan (CEO)
- Fred Grossman (Insider)
Learn More investors buying Coya Therapeutics stock.
